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Abstract
Obesity and its related severe consequences have been a major public health prob-
lem worldwide. A significant weight gain and intra-abdominal adipose tissue accumu-
lation are observed as women begin the menopausal transition. A number of clinical 
and basic research indicate that ovarian hormone may play a crucial role. However, the 
underlying mechanisms are largely unknown. In this chapter, we aim to systematically 
review the literature in the influences of ovarian hormone on the physiology of lipid 
and glucose metabolism, obesity-related hormone, and the regulation of body weight 
by the dietary intake, feeding behavior. A variety of research modalities have been 
used to explore the effects of MHT in perimenopausal women. Hence, we will also 
summarize the latest progress of MHT use on the effect of body mass, body fat redis-
tribution, and insulin resistance, which lead to protective cardiometabolic effects.
Keywords: menopause, ovarian hormone, estrogen, metabolism, obesity, 
menopausal hormone therapy, adipose distribution, insulin resistance, leptin,  
growth hormone, dietary intake
1. Introduction
Menopause is a special period for women, which is the end of menstrual cycle 
and fertility and also the start of a series of changes, such as hot flashes and mood 
changes. Energy metabolism also changes during menopausal transition, which 
is important and yet does not receive enough attention. Clinical surveys observed 
a trend of weight gain, increased food intake, intra-abdominal fat accumulation, 
increased low-density lipoprotein cholesterol and triglycerides, insulin resistance, 
and reduced energy expedition [1, 2]. All of these changes in energy metabolism 
add to the risk of diabetes and cardiovascular diseases (CVDs).
The characteristic and fundamental differences in postmenopausal women 
are the changes in ovarian hormones. Estrogen and progesterone decreased while 
androgen, follicular stimulating hormone (FSH), and luteinizing hormone (LH) 
increased [3]. Among them, the effect of the declination of estrogen level is most 
studied. Estrogen receptors are expressed in various tissues, such as brain, adipose 
tissue, liver, and intestinal mucosa, of which all regulate energy expenditure [4]. 
Apart from ovarian hormones, leptin, growth hormone, and others also affect 
energy homeostasis and will be discussed in the text.
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In this chapter, we summarize the evidence from clinical and animal studies and 
target to explain how hormonal changes in menopause lead to alterations in lipid 
Figure 2. 
Schematic illustration of possible pathophysiology underlying the ovarian hormone changes related to energy 
metabolism and obesity in menopause women.
Figure 1. 
Graphical overview on the contents of this chapter.
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and glucose metabolism, fat distribution, and food intake (Figures 1 and 2). We are 
also interested in the latest progress of the menopausal hormone therapy (MHT) 
and how it influences fat redistribution and metabolism (Figure 1).
2. Adipose distribution, metabolic consequences at menopause, and 
menopausal hormone therapy
2.1 The influence of menopause on adipose distribution and menopausal 
hormone therapy
2.1.1 Adipose distribution at menopause
The body adipose tissue distribution is different between males and females. The 
figure of men is pear shaped, since the adipose tissue tends to accumulate on the 
subcutaneous and intra-abdominal part. Whereas women’s figure is apple shaped, 
since women’s fat is more likely to accumulate on gluteal and femoral part [5]. 
However, mounting evidence indicated that postmenopausal women underwent 
deleterious changes of body adipose tissue distribution, from noncentral adiposity 
to central adiposity, which leads to an increased risk of CVD [6–8].
A number of factors contribute to the altered body adipose tissue distribution in 
postmenopausal women, including age, menopause, appetite, physical activity, and 
emotional changes, while age and menopause are the main reasons. A prospective 
study carried by Ho et al. concerning Chinese women aged 44–55 showed that the 
body fat percentage and central adiposity were higher among perimenopausal and 
postmenopausal women than that in premenopausal women [6]. Another study fol-
lowed up by Caucasus and black women for 4 years and found that menopause was 
related to total fat increase and visceral fat increase [7]. A meta-analysis revealed 
that the decrease in total leg fat percentage and increase in measures of central fat 
were related to menopause, while increasing age was a predominant contributor [8]. 
This epidemiological and clinical evidence suggests that ovarian hormone may play 
a major role in the regulation of adipose tissue distribution.
Since 1990s, accumulating evidence suggests that androgen receptor (AR), 
estrogen receptor (ER), and progesterone receptor (PR) are present in adipose 
tissues [5]. Ovarian hormones enter the cell and bind to their specific receptors, and 
then the complex regulates the transcription of targeted genes. Lipoprotein lipase 
(LPL) is one of the most important proteins that are involved in lipid deposition. 
LPL is the key enzyme hydrolyzing the circulating triglycerides into glycerol and 
free fatty acids, which accumulate in the adipose tissues. The hormonal regulation 
of LPL in adipose tissues is complicated. Generally, growth hormone and estrogen 
inhibit lipid accumulation by suppressing the activity of LPL, while cortisol and 
insulin appear to exert opposite function [5].
Iverius et al. found that fasting plasma LPL activity was inversely correlated 
with plasma estradiol levels and positively correlated with plasma-free testosterone 
in obese women [9]. One study observed that when 17β-estradiol patch was placed 
transdermally in the gluteal region of postmenopausal women, LPL in adipose 
tissue from beneath was significantly decreased compared to placebo group [10]. 
It is also found that compared to premenopausal women, postmenopausal women 
have lower LPL activity in femoral adipose tissue, whereas abdominal LPL activity 
is comparable [11]. Palin et al. found that estrogen regulates LPL activity in a dose-
dependent manner, the highest concentration of estrogen 10−7 mol/L significantly 
reduced LPL expression relative to control, while the lower concentration signifi-
cantly increased LPL expression relative to control [12]. However, whether estrogen 
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regulates LPL activity directly or indirectly remains unclear. A research from the 
rat model suggested that ovarian hormones exerted their regulation of LPL activity 
indirectly through their effect on growth hormone [13]. However, Homma and his 
colleagues found that estrogen markedly decreased the LPL mRNA using genetically 
manipulated cells and demonstrated a special sequence that was responsible for 
suppressing the LPL gene transcription by estrogen [14]. There might be a nonge-
nomic mechanism existing for the regulation of ovarian hormone, which responses 
more rapidly, since ER was found in cellular membranes of subcutaneous abdomi-
nal and omental human adipose tissues. But the mechanism has not been completely 
elucidated. It appears that various components of the membrane signaling systems 
were involved, including the cAMP cascade and the phosphoinositide cascade [5].
2.1.2 Menopausal hormone therapy-related body fat distribution
Since the increases in total body fat and abdominal fat are associated with hor-
monal changes during menopause transition period, MHT may help to ameliorate 
the unfavorable body fat redistribution and reduce the overall fat mass.
Our team found that in ovariectomized mice, the estrogen-treated group gained 
less weight and had significantly lower visceral adipose mass and smaller adipocyte 
size than nontreated group [15]. A randomized study found that hip and abdominal 
circumferences and fat mass/fat-free mass ratio over the abdomen in women who 
received only estrogen therapy were significantly declined [16]. Postmenopausal 
women who used continuous combined regimen of 17-β estradiol plus norethis-
terone acetate showed significantly reduced central fat accumulation as assessed 
by waist circumference and subcutaneous abdominal fat thickness after a 6-month 
follow-up [17]. One study concerning the randomized controlled clinical trial of 
the Women’s Health Initiative (WHI) showed that after 3 years of intervention 
with estrogen plus progestin, the treated group of women lost less lean soft tissue 
mass than the placebo group. Additionally, the women in the treated group had 
less upper-body fat distribution than the women in the placebo group [18]. Other 
studies compared different routes of estrogen replacement therapy and discovered 
that oral estrogen treatment resulted in an increase in fat mass of 5% and a decrease 
in lean body mass of 2%, which is equivalent to those occurring spontaneously over 
a 5–10-year period, whereas the transdermal estrogen did not bring a significant 
change in fat mass and lean mass [19, 20]. Though the conclusion is controversial, 
the International Menopause Society (IMS) puts it in their recommendation that 
menopausal abdominal fat accumulation can be ameliorated by estrogen therapy, 
with a reduction in overall fat mass, and maintain that a healthy diet and physical 
activity should also be included in weight management [21].
2.2  The influence of menopause on glucose metabolism and menopausal 
hormone therapy
2.2.1 Glucose metabolism at menopause
The incidence of glucose intolerance and insulin resistance increases after meno-
pause [22]. The underlying pathogenesis of impaired glucose metabolism, although 
not yet fully understood, has been linked to estrogen deficiency, which is one of the 
characteristic changes arising with menopause. Estrogen exerts its protective effects 
on glycometabolism via various ways:
1. Increase insulin synthesis: Estradiol-stimulated estrogen receptor α (ERα) 
activates the Src/MAPK pathway, phosphorylates the transcription factor 
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PDX-1, and enhances NeuroD1 nuclear localization and its binding to the 
insulin promoter [23]. As a result, insulin gene transcription is upregulated, 
and insulin synthesis increased.
2. Regulate insulin release: On one hand, estrogen inhibits basal insulin secretion, 
which is mainly mediated by estrogen receptor β (ERβ). After an overnight fast, 
ERβ knockout mice carry lower blood glucose level than their counterparts in the 
control group and ERα gene knockout group [24]. On the other hand, estrogen pro-
motes glucose-stimulated insulin secretion, which is mainly mediated by its plasma 
membrane receptor. This pathway regulates the activity of membrane-bound 
guanylate cyclase and activates protein kinase G. Subsequently, ATP-sensitive K+ 
channels close, and calcium channels open, triggering the insulin release [25].
3. Decrease insulin-mediated glucose uptake: Study suggests that the use of estro-
gen or combined estrogen-progesterone therapy in women may alter glycogen 
synthesis, GLUT4 translocation, and other early steps in the insulin-signaling 
pathway, which in turn decreases whole-body glucose uptake [26].
4. Reduce insulin resistance: Low estrogen is found to be an independent predictor 
of insulin resistance [27]. Elevated cytosolic free calcium may be the basis of 
insulin resistance. It is believed that estrogen as a calcium channel blocker may 
reduce cytosolic calcium, antagonizing the process of insulin resistance [28].
5. Protect pancreatic β cells against inflammation-induced apoptosis: Estrogen 
activates Src/MAPK, PI3K/Akt signaling pathway, upregulates liver receptor 
homolog −1, promotes glucocorticoid synthesis, suppresses interleukin-1 and 
interleukin-6 transcription, and thus protects human islets against inflamma-
tion-induced apoptosis [29].
6. Reduce pro-inflammatory cytokines: Estrogen reduces pro-inflammatory 
cytokines in adipose tissue. It is noted that the level of TNFα, MCP-1, IL6, and 
macrophages increases after oophorectomy in mice [30]. By inhibiting inflam-
matory responses, estrogen can improve the insulin sensitivity.
After menopause, the above protective effects are impaired due to a dramatic 
reduction in estrogen, leading to a decreased level of insulin synthesis and glucose-
stimulated secretion. At the same time, however, the inactivation and clearance of 
insulin are slowed in aging liver and kidney, and the serum insulin concentration 
exhibits an overall upward trend.
2.2.2 Menopausal hormone therapy-related glucose metabolism
MHT improves the quality of life in postmenopausal women by treating a range 
of symptoms with exogenous hormone supplement, using estrogen together with 
other hormones. However, current evidence concerning the effects of MHT on 
glycometabolism remains controversial.
It was found that a low estrogen status is more detrimental to glycometabolism. 
The second national health and nutrition survey in the United States revealed that 
the risk of Type 2 diabetes in postmenopausal women was significantly higher than 
premenopausal women. Moreover, 40~50% of menopausal women were reported 
to have reduced insulin sensitivity.
Further studies confirmed that estrogen has a dual effect on insulin sensitiv-
ity: appropriate estrogen improves insulin sensitivity, while high dose estrogen 
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promotes insulin resistance. In one study, insulin tolerance test was undertaken fol-
lowing the estrogen replacement using conjugated equine estrogen. K value indicat-
ing insulin sensitivity increased by 25% with the dosage of 0.625 mg but decreased 
by 24.7% with the dosage of 1.25 mg [31].
Borissova et al. found that estrogen in MHT can promote insulin secretion after 
glucose administration, improve insulin sensitivity, and correct fasting hyperinsu-
linemia in postmenopausal women with Type 2 diabetes [32]. Two large random-
ized, double-blind trials also found that estrogen replacement significantly reduced 
the incidence of diabetes compared with the control group, the incidence rates were 
3.5 versus 4.2% and 6.2 versus 9.5%, respectively [33, 34].
However, some scholars believe that estrogen is unfavorable for glycometabolism 
in view that high level of estrogen could result in a decrease in glucose tolerance in 
oral contraceptives users. Studies also showed that estrogen, when given beyond its 
physical dosage, induced the glucocorticoid secretion and thus increased the blood 
glucose level [35].
Lack of standardization for insulin sensitivity measurement, differences in 
the studied population, as well as types and routes of administration of hormone 
therapy may contribute to the discrepancies of effects of estrogen replacement on 
glycometabolism [36].
2.3  The influence of menopause on lipid metabolism and menopausal hormone 
therapy
2.3.1 Lipid metabolism at menopause
It is well known that estrogen has a significant effect on modulate lipid metabo-
lism. A variety of research show that total cholesterol (TC), triglycerides (TG), 
low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) 
increased in perimenopausal women, while menopause-related alternation in high-
density lipoprotein cholesterol (HDL-C) is inconsistent [1, 37–42]. Some studies 
reported a significant reduction, others found an increase in menopausal transition, 
and rest showed no changes in HDL-C, which El Khoudary has suggested that 
menopause-related alterations may influence other metrics of HDL that could not 
be fully reflected by just the cholesterol contents of HDL particles as measured by 
HDL-C [43].
The underlying mechanisms that estrogen and lipid interact at a molecular level 
to contribute to the risk of CVD are not clear. It has been reported that estrogen-
related receptor γ (ERRγ) regulates hepatic TG metabolism through the action 
phospholipase A2G12B [44], and polymorphic hepatic lipase is associated with 
estrogen modulate lipolysis of TG [45]. Della Torre et al. showed that liver ERα 
activity was essential for balanced lipid and TC metabolism, lack of ERα might 
lead to hepatic fat accumulation and nonalcoholic fatty liver disease [46]. Enza 
Distefano et al. suggested that estrogen activates the expression of LDL-receptor 
gene in HepG2 cells by tyrosine kinase signaling pathway [47]. Several research 
studies have suggested that estrogen can reduce circulating LDL-C but not choles-
terol synthesis by downregulation of hepatic and plasma PCSK9, which is a sup-
pressor of LDL receptors, in both animals and humans [48, 49]. Liu et al. reported 
that estrogen antagonizes oxidized LDL-induced secretion of macrophage matrix 
metalloproteinase-12 (MMP12,) and arterial stiffness that prevent from atheroscle-
rosis in women [50].
Recent studies of our group have linked glycerol channel aquaporin 7 (AQP7) to 
protective effect of estrogen against body fat redistribution and hepatic steatosis in 
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ovariectomized mice, indicating that AQP7 might be a novel checkpoint involved in 
the regulatory network of estrogen during menopausal obesity [15, 51]. Following 
up these studies, the molecular details that link AQP7 to estrogen were examined 
by analyzing the physical interactions between the promoter site of AQP7 and ER 
in our latest publication [52]. From there, we provided the first evidence that ER 
directly bound the estrogen response elements (EREs) in the promoter area of 
the Aqp7 gene and transcriptionally controlled AQP7 expression upon estrogen 
exposure. Therefore, there is solid ground for suggesting that Aqp7 is a direct target 
gene of ERs and may serve as a potential molecular target for the prevention of 
menopausal obesity.
In a recent study performed by Song et al., research focuses on the effects of FSH 
on lipid metabolism and has suggested that the marked increase of FSH expression 
postmenopausal combined with its receptors in liver may also reduce LDL-receptor 
level and subsequently result in a weakness of LDL-C endocytosis and an elevation 
of circulating LDL-C level [53].
Taken together, the above observations emphasize the gender differences and 
age independent on the lipid changes around the final menstrual period and suggest 
that ovarian hormone may influence the hepatic lipid synthesis, reduce the lipid 
circulation, upregulate the lipolysis, and lead to protective cardiometabolic effects. 
Growing body of literatures indicated several related functional proteins might play 
a crucial role in sex hormone’s regulation of lipid metabolism; however, presented 
findings of the studies as well as the conclusion need further verification, but they 
are promising. Therefore, the complex association of menopause, ovarian hormone, 
especially estrogen, and lipid metabolism needs further extensive experimentation.
2.3.2 Menopausal hormone therapy-related lipid metabolism
Prevention of weight gain and lipid metabolic disorder is important components 
in the healthcare of postmenopausal women. Although the latest guideline from 
IMS indicated that MHT may ameliorate perimenopausal intra-abdominal fat 
accumulation, whether the MHT might maintain the lipid level during menopause 
transition has not been mentioned [21].
Numerous studies have attempted to understand the metabolic consequences 
of MHT use and define the effects of different MHT regimens. Major studies 
have consistently found MHT decrease LDL-C, TC and lipoprotein (a) levels; 
however, findings regarding TG and HDL-C levels have been inconsistent [45, 
54–57]. Godsland reviewed the effect of different MHT regimens, estrogen alone, 
estrogen plus progestogen, raloxifene, or tibolone on plasma lipid and lipoprotein 
levels and found estrogen alone raise HDL-C and lower LDL-C and TC. Oral and 
transdermal estrogen had opposite effect on TG. The increases in HDL-C and TG 
when using estrogen alone were opposed according to the additional progesterone 
type. Specifically, effects arranged from the least to the greatest are dydrogesterone, 
medrogestone, progesterone, cyproterone acetate, medroxyprogesterone acetate, 
transdermal norethindrone acetate, norgestrel, and oral norethindrone acetate [58]. 
Stevens et al. suggested that MHT-related metabolic pathways is linked to multiple 
cellular processes, and the different MHT regimens might lead to distinct intracel-
lular signal transduction events which contributed to the disparate risks for some 
diseases, e.g. CVD and cancer, in menopausal women with MHT [59].
In conclusion, different MHT regimens have different effects on lipid metabo-
lism, exerting favorable and unfavorable changes. The choice for a particular 
regimen should consider individual demands, indications, complications, and 
lipid profile.
Hormone Therapy and Replacement in Cancer and Aging-related Diseases
8
2.4 Role of nonsex hormones in energy metabolism during menopausal transition
2.4.1 Role of leptin in energy metabolism at menopause
Leptin is a protein hormone encoded by obese genes and secreted by adipose tis-
sue. It has two effects on energy metabolism: on the one hand, it causes weight loss 
mainly by suppressing appetite. On the other hand, it has a number of effects on 
peripheral tissues: it can regulate energy balance by reducing lipid release into the 
blood circulation, reducing the output of triglycerides in target cells, and reducing 
the newly formed apolipoprotein B, which reduces the production of chylomicrons 
and low-density lipoprotein and increases apoA1, apoA IV, and apoE [60]. In obese 
people, the serum concentration of leptin is significantly elevated, which may be 
the result of leptin resistance [61]. At the same time, leptin plays a special role in 
maintaining normal reproductive function. The maintenance of human reproduc-
tive function requires adequate nutrition and storage of metabolic fuels, and leptin 
is a messenger with this signal [62, 63]. People who are emaciated lack such a signal.
In the peri-menopausal obesity, the role of leptin is still not clear. Several studies 
have found that the leptin level in the obese women was significantly higher than 
that in the nonobese women, but there is no significant difference in serum leptin 
levels pre and post menopause [64], and menopause does not significantly affect 
leptin production. Serum leptin levels were significantly positively correlated with 
BMI and waist circumference [65].
Moreover, in the studies of leptin level in different sexes, it was found that peri-
menopausal women had significantly higher level of leptin than men (even after 
adjusting for differences in male and female body weights) [66]. In the relationship 
between leptin and fat mass, it is different from gender. On the one hand, it is 
because of the inhibitory effect of androgen in blood on leptin. On the other hand, 
the difference in the amount of leptin in different fat distributions may also play a 
role. In fact, subcutaneous fat expresses more leptin mRNA than visceral fat [67], 
while male subcutaneous fat is less than female, so adipose tissue in males may 
produce less leptin than female adipose tissue. This can explain the difference in 
fat content in different genders, but it cannot explain that women before and after 
menopause have different fat distributions but have similar leptin levels. Kastin 
et al. studied the transfer of peptides from the blood into the brain in mice after 
ovariectomy and found that the transport of leptin into the brain was lower than 
that before ovariectomy [68]. Thus, they suggested that the weight gain caused 
by the loss of ovarian function in mice might be related to the decrease in leptin 
transported into the brain.
2.4.2 Role of growth hormone in energy metabolism at menopause
Growth hormone (GH) levels are lower in postmenopausal women than that in 
premenopausal women. Postmenopausal women have changes in body weight and 
body fat distribution, which may also be caused by changes in growth hormone axis 
function [69]. Snel et al. found that the fat mass in GH-deficient adults increased, 
and lean mass decreased [70], and this change could be reversed after supplementa-
tion with GH, thus confirming the importance of GH in regulating fat content.
GH regulates body weight through the hypothalamic-pituitary axis. Two 
peptides, growth hormone releasing hormone (GHRH) and growth hormone 
release inhibiting hormone (GHRIH), secreted by the hypothalamus, activate 
and inhibit the release of pituitary GH. The stress response of GH to GHRH in 
postmenopausal women decreases [71]. This response is similar to that in obese 
and elderly population; MHT supplementation in postmenopausal women can 
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reconstitute GH response to GHRH. This shows that the neuroendocrine release of 
GH plays an important role in the control of neutral steroid hormones. On the other 
hand, high GH concentration may have exerted negative feedback by hypothalamic 
GHRIH [72]. The use of arginine in postmenopausal women does reconstitute the 
response of GH to GHRIH [73], which has nothing to do with BMI [71]. Therefore, 
we can assume that obesity, menopause, and aging are the characteristics of normal 
neuroendocrine changes caused by excessive effects of GHRIH, but the intrinsic 
relationship between them remains to be further studied.
2.5 Dietary intake at menopause
Incidence of overweight and obesity is increased in perimenopausal and meno-
pausal women, which is an important public health concern. One of the reasons for 
increasing obesity during the menopausal transition is the increase in food intake. A 
combination of biological and psychological factors exerts potent influence on the 
regulation of appetite and food intake.
2.5.1 Estrogen and the central control of appetite
Women during the menopausal transition had decreased estrogen. Estrogen 
participates in the regulation of energy homeostasis, as evidenced by an increase 
in food intake and obesity in ovariectomized rats. In concordance, clinical evi-
dence showed that hunger, desire to eat, and prospective food consumption are all 
increased during the menopausal transition, while fasting fullness is decreased. 
This trend persisted in the later postmenopausal years [74]. However, both animal 
and human studies indicate that overeating due to the lack of estrogen can be 
ameliorated by estrogen replacement therapy [75].
Control of appetite is mainly performed in the hypothalamus of the central ner-
vous system. Located in this region are arcuate, ventromedial, and paraventricular 
nuclei. Two major populations of arcuate neurons influence food intake in opposite 
directions. Neurons that extend projections to the lateral hypothalamic area express 
neuropeptide Y and Agouti-related peptide, which stimulate food intake and 
decrease energy expenditure. In other words, they extend orexigenic effects. Other 
arcuate neurons extend projections to the paraventricular nuclei and express proo-
piomelanocortin (POMC) and cocaine-amphetamine-regulated transcript (CART), 
which inhibit food intake and increase energy expenditure. Therefore, they extend 
anorexigenic effects [76, 77]. Estrogen acts as both a direct and an indirect control 
of appetite and food intake, modulating both anorexigenic and orexigenic signals 
in hypothalamus [78]. Estrogen regulates the function of the hypothalamic nuclei 
through complex processes. While ERα is abundantly expressed in the rodent brain 
in ventromedial, arcuate, and paraventricular and the medial preoptic area, ERβ 
expression is significantly lower [79]. Estrogens directly act on POMC neurons and 
regulate their cellular activity. ERα mRNA level in arcuate POMC neurons fluctu-
ates over the course of the menstrual cycle, with the most dramatic increase on the 
day of proestrus, when E2 concentration is the highest [77]. In concordance, Xu 
et al. demonstrated that hypothalamic-specific deletion of ERa in steroidogenic fac-
tor-1 (SF1) neurons reduces energy expenditure. Deletion of ERa in POMC neurons 
alone increases appetite. Simultaneous deletion of ERa in POMC and SF1 neurons 
can add up these two effects and lead to hypometabolism and hyperphagia [80].
Peptidergic systems known to regulate ingestive behavior include ghrelin, 
neuropeptide Y (NPY), and melanin-concentrating hormone (MCH). Ghrelin 
peptide is a hunger-stimulating hormone, which is not only produced in the 
stomach by parietal cells but also produced in different areas of the hypothalamus, 
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such as the aforementioned arcuate and paraventricular nuclei [81, 82]. Ghrelin 
regulates food intake by activating the growth hormone receptor according to the 
fluctuation in carbohydrate and lipid levels. Ghrelin also antagonizes the function 
of leptin, which promotes a sense of fullness. The antagonizing effect acts through 
the neuropeptide Y/Y1 receptor pathway, which increases gene expression of NPY 
and augment food intake [83].
NPY increases food intake potently through the function of the arcuate and 
paraventricular area in hypothalamus [84]. Estrogen inhibits the orexigenic activity 
of NPY. This inhibitory action stems from the reduced NPY mRNA expression and 
receptor activity by estrogen [85].
Melanin-concentrating hormone (MCH) promotes feeding behavior by direct 
action on the lateral nucleus in hypothalamus [86]. The arcuate and POMC neurons 
can stimulate the MCH activity [87]. Ovariectomized rats treated with estradiol 
demonstrated reduced orexigenic effect of MCH [88], which is hypothesized to be a 
direct effect of the reduced expression of MCH mRNA or the decreased affinity of 
the MCH receptor [89].
2.5.2 Stress and feeding behavior
Stress has been tied to a tendency to overeat and a preference for high-fat and 
high-sugar foods. Animal studies showed that chronic stress stimulates food intake 
and inhibits hypothalamic-pituitary-adrenal axis activity induced by acute stress 
[90]. In humans, food craving after stress can be predicted by high cortisol reactiv-
ity in response to stress. Epel et al. found that premenopausal women exposed 
to a stressful situation had higher cortisol levels and experienced higher calorie 
consumption, and they also tend to prefer sweets. Negative mood induced by stress 
also leads to greater food consumption [91]. As women experiencing menopausal 
transition, they are exposed to a lot of distressing symptoms, such as hot flashes, 
negative mood, poor sleep, recurring infections of the urogenital tract, and so on. 
Stress arises, which may increase their eating behavior.
Further, stress situations can decrease gastric motility. Estrogen has syner-
gistic actions with stress mediators and interacts with neuromodulators [92]. 
Estrogen also influences gut function by inhibiting smooth muscle contraction. 
Premenopausal and postmenopausal women demonstrated a decrease in gastric 
motility under stress, which was similar to the general population. However, the 
perimenopausal women exhibited lower basal gastric motility but did not reveal 
a decreased gastric motility in response to stress. This indicated that many gastric 
changes during menopause are a rapid response to decreased estrogen levels, which 
happens quickly and can recover with time even without estrogen replacement [93].
Gaining better understanding of the mechanisms of increased appetite during 
menopausal transition promises to open novel therapeutic solutions for this popula-
tion. Since the lack of estrogen plays a key role in the disturbances of food intake, 
MHT is one of the solutions to prevent unfavorable overeating, metabolic distur-
bances, and obesity.
3. Conclusions
With the aging of world population, the health issue of postmenopausal 
women has been unprecedented concerned. Obesity is associated with a decline 
of lifespan. Especially, the increased risk of weight gain, centrally accumulation 
of body fat, and energy metabolism disorders during the menopausal transition 
lead to further CVD and rise overall mortality in women. An early intervention of 
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